11.08.2026 • News

Asahi Kasei Licenses Novel Electrolyte in China

The partnership gives Asahi Kasei a foothold for expanding its electrolyte technology to the Chinese market.

company representatives
Yuichi Taka of HighChem, Yueyuan Long of HighChem Shanghai, and Osamu Matsuzaki and Yuto Iizuka of Asahi Kasei at Asahi Kasei’s headquarters.
© Asahi Kasei

Asahi Kasei has concluded a non-exclusive license agreement with HighChem Shanghai, an affiliate of HighChem, with operations focused on trading in China. Through this partnership, HighChem Shanghai will produce and sell acetolyte, a novel acetonitrile-containing electrolyte based on Asahi Kasei’s technology, in China. The collaboration advances Asahi Kasei’s licensing strategy to accelerate sales of the electrolyte to battery manufacturers in China.

The agreement between HighChem Shanghai and Asahi Kasei comes as China’s market for high-performance lithium-ion batteries is rapidly expanding due to the growth of electric vehicles (EVs) and energy storage systems (ESS). This marks the first license agreement for Asahi Kasei’s novel electrolyte technology in China, and grants HighChem Shanghai a non-exclusive license to produce and sell the electrolyte for the local market.

“Having focused on the lithium-ion battery business for nearly 20 years, HighChem has knowledge and extensive business experience in the Chinese market,” said Yueyuan Long, General Manager of HighChem Shanghai. “Acetolyte offers excellent low-temperature performance, and we believe that our collaboration with Asahi Kasei will enable us to maximize the value of this technology and open up new possibilities for the battery industry.”

Osamu Matsuzaki, Senior Executive Officer of Asahi Kasei and Head of Corporate R&D, added, “We have steadily expanded the Acetolyte™ business through licensing partnerships in Europe. This first license agreement in China represents a significant advance in the global extension of our technology. By partnering with HighChem Shanghai, we can deliver innovative solutions to customers in this major market while further strengthening our licensing-based growth strategy.”

Under its current medium-term management plan announced in April 2025, Asahi Kasei is pursuing Technology-value Business Creation (TBC), an initiative to monetize the company’s extensive intangible assets, including patents, know-how, data, and algorithms, by providing them in various forms, including licensing.

This approach allows for swift, asset-light commercialization that accelerates new business creation and maximizes value for customers and partners. Through such licensing-based business development, Asahi Kasei aims to conclude at least 10 new license agreements during fiscal 2025–2027, with a cumulative profit contribution of ¥10 billion or more by around 2030.

Company

Logo:

Asahi Kasei Europe

Fringsstraße 17
40221 Düsseldorf
Germany

Company contact







Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

Article

The State of the US Specialty Chemicals Industry
Reshaping Specialty Chemicals Manufacturing

The State of the US Specialty Chemicals Industry

SOCMA's Jenn Klein examines how specialty chemical manufacturers — the invisible backbone behind pharmaceuticals, electronics, agriculture, and energy — are navigating supply chain shifts, policy uncertainty, and constant change while remaining resilient, disciplined, and focused on execution.

most read

Photo

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.